Big Pharma GCCs In India: From Back-Office Ops To Innovation Catalysts

India is seeing a flurry of activity with big pharma either establishing or expanding their global capability centers in the country. Can these hubs reshape the contours of industry’s operating model across a range of functions and perhaps spawn a pipeline of new leaders along the way?

Pharma bets big on GCCs in India

“The things I hear about when I walk around the floors in Hyderabad are the things that are on my desk as CEO of Novartis,” said Vas Narasimhan at a press meet last year, referring to the increasingly pivotal contribution of the company’s Global Capability Center (GCC) in India to the Swiss group’s global operations.

Novartis’ Hyderabad operations have gone from doing “back-office processing work” to providing high-quality support services across a diverse range of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from In Vivo

Pharma’s Space Trails Entering Transformative Era

 

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Surgical Robotics CEOs Talk Metrics For Success, Valuations And Competition

 
• By 

Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.

Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds

 
• By 

Richard Wilson, SVP and primary focus lead for genetic regulation at Astellas, talks with In Vivo about the company's commitment to AAV as a gene therapy delivery vehicle, recent company investments and the regulatory environment under Trump's FDA.

‘A Small Medtech Industry Ecosystem With An Outsized Global Influence’

 
• By 

Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.

More from Innovation

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By 

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

IMMA Starts A Silent Revolution By Making IVF Journey Digital, Predictable And At Home

 
• By 

IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.